Sign in
CompletedPhase 3

Comparative Effectiveness of Gadopiclenol for Evaluation of Adult Congenital Heart Anatomy and Hemodynamics

Key facts

Who runs it
University of California, San Diego
Where
San Diego, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 3
People taking part
161 people enrolled
Started
5 Aug 2024
Ended
23 Aug 2026
Type of study
Interventional, 4 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Gadopiclenol
  • Gadobenate dimeglumine
Record updated
3 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (8)Hide the full registry criteria

Who can take part

  • Adult patients (≥ 18 years old)
  • History of congenital heart disease and scheduled to undergo standard of care cardiac MRI and chest MRA as part of routine clinical care
  • English is patient's primary spoken language

Who cannot take part

  • History of hypersensitivity reaction to gadolinium based contrast agent
  • Patients with ongoing acute kidney injury (AKI) or severe, chronic kidney disease (GFR < 30 mL/min/1.73m2)
  • Pediatric patients
  • Pregnant patients
  • English is not the patient's primary spoken language

Where in United States

  • University of California San Diego HealthSan Diego, United States

About the trial

What the trial wants to find out

The goal of this clinical trial is to learn how well and at what doses gadopiclenol, a new intravenous (IV) contrast agent used for MRI, works to produce high-quality MRI images of the heart, in patients with a history of congenital heart disease, when compared to gadobenate dimeglumine, the IV contrast agent that is normally used at our institution for heart (cardiac) MRI. The main questions it aims to answer are:

Read full original descriptionShow less

* Does using gadopiclenol result in similar or superior image quality, similar signal-to-noise ratio (SNR), and similar flow measurements with 4-dimensional (4D) flow cardiac MRI when compared to gadobenate dimeglumine? * At what dose(s) does gadopiclenol result in similar image quality (using the above metrics) for cardiac MRI when compared to gadobenate dimeglumine?

Researchers will compare cardiac MRI images obtained after administration of gadopiclenol to cardiac MRI images obtained after administration of gadobenate dimeglumine (called the standard of care treatment) to see if the images are of similar or superior quality.

Participants will:

* Be randomized to receive either gadopiclenol at one of three different doses or gadobenate dimeglumine before their congenital heart cardiac MRI * Undergo their congenital heart cardiac MRI as they would during the course of normal clinical care.

The 4 groups in the trial

  • Gadobenate dimeglumine 0.15 mmol/kg (standard of care)Existing treatment, for comparison

    Treatment: Gadobenate dimeglumine

  • Gadopiclenol 0.075 mmol/kgTreatment being tested

    Treatment: Gadopiclenol

  • Gadopiclenol 0.10 mmol/kgTreatment being tested

    Treatment: Gadopiclenol

  • Gadopiclenol 0.15 mmol/kgTreatment being tested

    Treatment: Gadopiclenol

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
3 November 2026